
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. is demonstrating strong growth potential as its EsoGuard test volume rose by 2% year-over-year to 2,841 tests in Q3 2025, reflecting both incremental quarterly increases and year-on-year gains. The company anticipates substantial revenue growth as it increases coverage from various payers, including Medicare, which will enhance its market reach and financial performance. Positive developments, such as a constructive meeting regarding Medicare coverage and increased engagement with a significant portion of the addressable population, position Lucid Diagnostics favorably for future growth and market expansion.
Bears say
Lucid Diagnostics Inc. demonstrated a negative financial performance in 3Q25, missing consensus revenue estimates while reporting a pro forma net loss of $10.3 million, which exceeded prior estimates and illustrated a concerning trajectory in earnings per share. The company's ability to gain traction with its EsoGuard product has been hindered by slower-than-anticipated adoption rates and potential issues with insurance coverage, leading to a decline in test numbers processed compared to previous quarters. Additionally, ongoing risks related to balance sheet stability, regulatory approvals, and competitive pressures further underscore the challenges facing Lucid Diagnostics, casting a shadow over its future growth prospects.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares